Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, c2002-
    • Subject Terms:
    • Abstract:
      Background: Osteosarcomas are the most common primary malignant tumors of bone, showing complex chromosomal rearrangements with multiple gains and losses. A frequent deletion within the chromosomal region 3q13.31 has been identified by us and others, and is mainly reported to be present in osteosarcomas. The purpose of the study was to further characterize the frequency and the extent of the deletion in an extended panel of osteosarcoma samples, and the expression level of the affected genes within the region. We have identified LSAMP as the target gene for the deletion, and have studied the functional implications of LSAMP-reexpression.
      Methods: LSAMP copy number, expression level and protein level were investigated by quantitative PCR and western blotting in an osteosarcoma panel. The expression of LSAMP was restored in an osteosarcoma cell line, and differences in proliferation rate, tumor formation, gene expression, migration rate, differentiation capabilities, cell cycle distribution and apoptosis were investigated by metabolic dyes, tumor formation in vivo, gene expression profiling, time-lapse photography, differentiation techniques and flow cytometry, respectively.
      Results: We found reduced copy number of LSAMP in 45/76 osteosarcoma samples, reduced expression level in 25/42 samples and protein expression in 9/42 samples. By restoring the expression of LSAMP in a cell line with a homozygous deletion of the gene, the proliferation rate in vitro was significantly reduced and tumor growth in vivo was significantly delayed. In response to reexpression of LSAMP, mRNA expression profiling revealed consistent upregulation of the genes hairy and enhancer of split 1 (HES1), cancer/testis antigen 2 (CTAG2) and kruppel-like factor 10 (KLF10).
      Conclusions: The high frequency and the specificity of the deletion indicate that it is important for the development of osteosarcomas. The deletion targets the tumor suppressor LSAMP, and based on the functional evidence, the tumor suppressor function of LSAMP is most likely exerted by reducing the proliferation rate of the tumor cells, possibly by indirectly upregulating one or more of the genes HES1, CTAG2 or KLF10. To our knowledge, this study describes novel functions of LSAMP, a first step to understanding the functional role of this specific deletion in osteosarcomas.
    • References:
      Lab Invest. 2011 Aug;91(8):1195-205. (PMID: 21519327)
      BMC Res Notes. 2010 Aug 08;3:223. (PMID: 20691109)
      PLoS One. 2012;7(10):e48086. (PMID: 23133552)
      J Transl Med. 2013 May 16;11:122. (PMID: 23680400)
      Cancer Cell. 2003 Nov;4(5):405-13. (PMID: 14667507)
      Cytogenet Genome Res. 2008;122(1):5-15. (PMID: 18931480)
      BMC Cancer. 2004 Aug 07;4:45. (PMID: 15298715)
      Biofactors. 2010 Jan-Feb;36(1):8-18. (PMID: 20087894)
      Int J Cancer. 1998 Jun 10;76(6):903-8. (PMID: 9626360)
      J Neurosci. 1988 Dec;8(12):4653-61. (PMID: 3199199)
      PLoS One. 2011 Mar 14;6(3):e17522. (PMID: 21423731)
      Bioinformatics. 2003 Jan 22;19(2):185-93. (PMID: 12538238)
      Nucleic Acids Res. 2013 May;41(9):4976-87. (PMID: 23558749)
      Nat Rev Cancer. 2003 Sep;3(9):685-94. (PMID: 12951587)
      J Cell Biochem. 1998 Feb 1;68(2):226-36. (PMID: 9443078)
      Sarcoma. 2012;2012:627254. (PMID: 22685381)
      Mol Psychiatry. 2009 Jun;14(6):601-13. (PMID: 18268500)
      Cancer. 1995 Jan 1;75(1 Suppl):203-10. (PMID: 8000997)
      Br J Cancer. 2001 Sep 1;85(5):713-20. (PMID: 11531257)
      J Urol. 2004 Jan;171(1):200-3. (PMID: 14665876)
      PLoS One. 2012;7(11):e48262. (PMID: 23144859)
      Bioinformatics. 2001 Apr;17(4):369-70. (PMID: 11301307)
      Clin Cancer Res. 2011 Apr 15;17(8):2110-9. (PMID: 21372215)
      J Cell Sci. 2004 Aug 1;117(Pt 17):3961-73. (PMID: 15265982)
      Genes Chromosomes Cancer. 2012 Jul;51(7):696-706. (PMID: 22454324)
      PLoS One. 2012;7(9):e43720. (PMID: 22957032)
      Cancer Res. 2010 Jan 1;70(1):160-71. (PMID: 20048075)
      Clin Cancer Res. 2005 Aug 15;11(16):5764-8. (PMID: 16115914)
      Eur J Cell Biol. 2003 Sep;82(9):483-93. (PMID: 14582536)
      Clin Cancer Res. 2010 Aug 15;16(16):4256-67. (PMID: 20610556)
      J Bone Miner Res. 2006 Jun;21(6):921-33. (PMID: 16753023)
      Genes Chromosomes Cancer. 2005 Feb;42(2):158-63. (PMID: 15540165)
      BMC Cancer. 2010 May 13;10:202. (PMID: 20465837)
      Cancer Cell. 2002 Sep;2(3):175-8. (PMID: 12242149)
      Stem Cells Dev. 2012 Apr 10;21(6):873-83. (PMID: 21756067)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Neuron. 1995 Aug;15(2):287-97. (PMID: 7646886)
      Genes Chromosomes Cancer. 2009 Aug;48(8):679-93. (PMID: 19441093)
      Br J Cancer. 2013 Oct 15;109(8):2228-36. (PMID: 24064976)
      Cancer Res. 1992 May 1;52(9):2419-23. (PMID: 1568211)
      Oncol Rep. 2009 Oct;22(4):815-23. (PMID: 19724860)
      J Cell Biochem. 2007 Oct 15;102(3):539-48. (PMID: 17729309)
      Int J Oncol. 2009 Oct;35(4):775-88. (PMID: 19724913)
      FEBS Lett. 2004 Aug 27;573(1-3):83-92. (PMID: 15327980)
      Blood. 2012 Mar 8;119(10):e67-75. (PMID: 22234698)
      Clin Cancer Res. 2005 Mar 1;11(5):1809-14. (PMID: 15756003)
      Hum Mol Genet. 2009 Apr 15;18(8):1464-70. (PMID: 19228774)
    • Molecular Sequence:
      GEO GSE52089
    • Accession Number:
      0 (Antigens, Neoplasm)
      0 (Antigens, Surface)
      0 (Basic Helix-Loop-Helix Transcription Factors)
      0 (CTAG2 protein, human)
      0 (Cell Adhesion Molecules, Neuronal)
      0 (Early Growth Response Transcription Factors)
      0 (GPI-Linked Proteins)
      0 (Homeodomain Proteins)
      0 (KLF10 protein, human)
      0 (Kruppel-Like Transcription Factors)
      0 (RNA, Messenger)
      0 (Transcription Factor HES-1)
      0 (limbic system-associated membrane protein)
      149348-15-2 (HES1 protein, human)
    • Publication Date:
      Date Created: 20140603 Date Completed: 20150112 Latest Revision: 20231104
    • Publication Date:
      20240829
    • Accession Number:
      PMC4029956
    • Accession Number:
      10.1186/1476-4598-13-93
    • Accession Number:
      24885297